BioMerieux (BIMp)

CBOE (Paris)Healthcare

€104.5
+€1 (+1.0%)
Last close

January 21, 2026 at 16:30 UTC

Interactive Chart
BIMp
1H
3H
6H
12H
1D
1W
1M
3M
6M
12M (YTD)
2Y
5Y
All
About BioMerieux

Name

BioMerieux

CEO

Pierre Boulud

Industry

Healthcare

Year Founded

1963

Employees

14,147

BioMerieux is an in vitro diagnostics company that designs systems, reagents, and software used in clinical laboratories and public-health settings. The portfolio supports microbiology, immunoassay, and molecular workflows, and products are developed to fit validation and quality routines in regulated environments. Manufacturing and field support operate under a single quality framework, and documentation is written for accreditation bodies as well as lab managers. Country organizations handle market access and training while core engineering and medical information remain centralized. The company’s stance in the healthcare ecosystem is method first: evidence, labeling, and service are kept in step so laboratories can adopt platforms without rewriting daily practice. Activity spans many regions with logistics tuned to cold-chain and service windows.

Analyst Ratings
Consensus Recommendation
Analyst consensus: 4 Buy, 5 Hold, 15 Sell
Buy4
Hold5
Sell15
Fundamentals & Financials
Revenue (TTM)
€4.1B
Net Income (TTM)
€377.9M
EPS (TTM)
€3.2
ROA (TTM)
7.04%
Current Ratio
2.27
Dividend Yield
0.1%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement (Quarterly)
ItemQ2 2025
Revenue€2,043.8M
Cost of Sales€876,900K
Gross Profit€1,166.9M
Operating Income€209,200K
Net Income€161,000K
EPS€1.36
Technical Indicators

BioMerieux's Technical Indicators Summary

BIMp is exhibiting a broadly bearish profile as it trades slightly above the VWAP but below most key moving averages, including the 200-day EMA, which suggests downward pressure remains intact. Momentum indicators such as the MACD and CCI confirm weakening momentum, while the RSI hovers near oversold territory without signaling a strong reversal. The ADX indicates a moderately strong trend, leaning bearish, and volume trends on the OBV support selling pressure. Despite a low Stochastic and Williams %R hinting at potential short-term relief, overall technical conditions favor continued caution, with resistance near the classic pivot around 103.70. The technical takeaway is that BIMp remains under sustained selling influence amid persistent downward momentum.

Buy
4 signals
Neutral
5 signals
Sell
15 signals
Overall: Bearish63% Bearish signals
IndicatorValue
RSI (14)
31.66
Stochastic %K (14, 3, 3)
10.15
CCI (20)
-179.32
WPR (14)
-94.20
Momentum (10)
-11.70
MFI
28.84
MACD Level (12, 26)
-0.94
Bollinger Bands
$103.17 - $115.82
ATR (14)
$2.16 (2.10%)
ADX (14)
25.64
OBV
682,975
VWAP
$103.07
Classic Pivot Point
$103.70
Fibonacci Pivot Point
$103.70
Simple Moving Averages
$108.05 - $115.28(5 indicators)
Exponential Moving Averages
$107.03 - $113.34(5 indicators)
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.

Today's Snapshot

By the close, BIM.PA remained slightly above yesterday’s 103.60, with a small 0.772% gap leaving it around 104.40. By the final tick, sector performance was mildly positive (1.11%), giving a light assist to the overall tone. BIM.PA's slight gain amid positive sector performance suggests cautious optimism without clear company-specific news.

Price Change

from €103.6 close

+€0.8

Trading Volume

Below avg (160.2K)

36.2K

vs S&P 500 Today

Moderate Underperformance

-0.32%

52-Week Position

Near lows

8.1%

Updated: January 21, 2026 at 16:04 UTC

Quote Summary
OpenPrevious Close
€103.3€103.6
Day Range52 Week Range
€103.2 - €105€102.3 - €128.3
VolumeAvg. Volume
142K111.9K
Market CapP/E Ratio
€12.3B32.9